Healthcare Industry News: multi-leaf collimator
News Release - April 1, 2014
Elekta to demonstrate the synergy of technology and people at ESTRO 33VIENNA, April 1, 2014 -- (Healthcare Sales & Marketing Network) -- ESTRO Booth #6200 – At ESTRO33, Elekta will demonstrate a comprehensive array of advanced solutions for cancer management. These products include the Versa HD™ treatment system, Monaco® 5 treatment planning system and Esteya® electronic brachytherapy system for treating skin cancer. ESTRO33 convenes April 4-8 at the Reed Messe Vienna Congress Centre. Follow @Elekta for live tweets from the show floor.
Elekta's theme for this year's ESTRO, The Power of Care, emphasizes the synergy of technology and people working together to support positive patient outcomes. Versa HD embodies this theme through its flexibility, speed and accuracy, in addition to an array of anatomic packages designed to address unique clinical challenges, making it easy to customize a system that meets clinic and patient needs. Versa HD is designed to deliver conventional therapies for indications commonly seen in the clinic, while also permitting treatment of complex cancers that require extreme targeting accuracy.
Medical University Innsbruck is the first center in Austria to begin treating patients with Versa HD. Since January 14, the clinic has put 55 new patients on the Versa HD schedule and is averaging 23 treatments per day, mostly patients with small tumors in the brain and lung.
"The dose rate we're currently using with Versa HD is a factor of up to three times higher than that of the other treatment machines we use here, which helps keep treatment times reasonable in complex cases," says Medical University Innsbruck physicist Paul Eichberger. "The Agility multi-leaf collimator also provides greater precision and its fast leaf speeds increase delivery speed. Because we can conform more closely to the tumor margins, we find we can increase the dose to the tumor while decreasing side effects – all within a standard treatment time."
ESTRO will serve as the European launch of Esteya electronic brachytherapy for skin cancer. Esteya, a form of high dose rate (HDR) brachytherapy, brings a miniaturized X-ray source close to the cancerous site, enabling the application of radiation. This direct delivery enables Esteya to focus more therapeutic radiation on the disease target and to minimize radiation to surrounding tissues and organs. Esteya requires only minimal room shielding, allowing the treatment to occur virtually anywhere patients are seen.
Monaco 5 will make its ESTRO debut. The latest version of this advanced treatment planning system consolidates the best of Elekta's treatment planning solutions into a single system and features a new system architecture and graphical user interface.
"Monaco 5 provides us with Segment Shape Optimization for the dynamic MLC, in addition to feet-first orientation of the CT scan, which enables us to set up CT scans for patients who have tumors in the lower abdomen or extremities," says Jens Fleckenstein, PhD, physicist at University Medical Centre Mannheim (Mannheim, Germany). "We also will be able to develop 3D plans, and there are some contouring features – such as a pearl tool that allows you to draw freehand contours – that are much better in Monaco 5."
Elekta also will highlight Identify™, a system utilizing radiofrequency identification (RFID) technology for full confidence in patient and equipment identification during patient setup, thus increasing patient safety. From the moment the patient enters the CT or treatment room, Identify positively verifies the right patient and the accessories required for their treatment.
Elekta lunch symposium
Elekta will host a lunch symposium titled "The Power of Care," on April 5, from 13:00-14:30, at the Reed Messe Vienna Congress Centre in room Lehar 1-2-3, first floor. Presentations will include Versa HD, Monaco 5 and Esteya. During the symposium, three Elekta users will share their knowledge and experience using these latest solutions and how they help improve their ongoing drive toward optimized care.
Learn more at www.elekta.com/ESTRO.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.